Stockreport

Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

Mersana Therapeutics, Inc.  (MRSN) 
Last mersana therapeutics, inc. earnings: 2/28 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: mersana.com/about-mersana
PDF Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 [Read more]